Intentional rechallenge: does the benefit outweigh the risk?

Abstract:

:Rechallenge is defined as the readministration of a medication suspected of being a possible cause of an adverse reaction and which has been discontinued as result. It may be unintentional when the appearance of a reaction was initially not attributed to the medication. A rechallenge may be intentional when a prescriber decides that the benefit of rechallenge will outweigh its risk. When considering intentional rechallenge, one should take into account the benefit/risk balance of the suspected causative medication, and the benefit/risk balance of the best available alternative treatment or no treatment. Clinical knowledge is essential in benefit/risk assessment but there is currently no suitable tool to guide the decision on rechallenge. This article aims to propose points to consider in the creation of reaction-specific algorithms for risk assessment and management in the case of drug rechallenge.

journal_name

Drug Saf

journal_title

Drug safety

authors

Stanulović V,Venegoni M,Edwards B

doi

10.1007/s40264-013-0020-3

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

155-61

issue

3

eissn

0114-5916

issn

1179-1942

journal_volume

36

pub_type

杂志文章
  • Cytokine-induced autoimmune disorders.

    abstract::Cytokines are now commonly used in the treatment of many conditions, especially cancer, haematological malignancies and chronic viral hepatitis. With some of these cytokines, clinical induction and/or exacerbation of autoimmune manifestations have been observed. This has been the case with interferon-alpha and interfe...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199717020-00002

    authors: Miossec P

    更新日期:1997-08-01 00:00:00

  • Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

    abstract::The prevalence of pain is high in multimorbid patients and they can experience a multitude of painful conditions. The changes in physiology and homeostasis associated with multimorbidity and increasing age and the immature metabolism of neonates all increase the risk of toxicity from analgesics. Altered pharmacokineti...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199818060-00006

    authors: Wilder-Smith CH

    更新日期:1998-06-01 00:00:00

  • Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

    abstract:BACKGROUND AND OBJECTIVE:Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or 'statins', launched in the UK in March 2003. Our objective was to monitor the post-marketing safety of this drug, prescribed in primary care in England, using prescription-event monitor...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200730020-00005

    authors: Kasliwal R,Wilton LV,Cornelius V,Aurich-Barrera B,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

    abstract::Cholinesterase inhibitors are currently the most established treatment strategy in Alzheimer's disease. The treatment effect appears mainly to be symptomatic. Effects on progression of the disease following long term treatment, and possible neuroprotective effects, have been investigated. Delay until nursing home plac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199819060-00004

    authors: Nordberg A,Svensson AL

    更新日期:1998-12-01 00:00:00

  • Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.

    abstract::The entire drug safety enterprise has a need to search, retrieve, evaluate, and synthesize scientific evidence more efficiently. This discovery and synthesis process would be greatly accelerated through access to a common framework that brings all relevant information sources together within a standardized structure. ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0189-0

    authors: Boyce RD,Ryan PB,Norén GN,Schuemie MJ,Reich C,Duke J,Tatonetti NP,Trifirò G,Harpaz R,Overhage JM,Hartzema AG,Khayter M,Voss EA,Lambert CG,Huser V,Dumontier M

    更新日期:2014-08-01 00:00:00

  • In vitro models.

    abstract::The development of in vitro models is advancing rapidly, with the application of cell culture methods as an alternative to animals in toxicological screening; non-cellular systems are also being used. Any screening test, whether for detecting irritants, carcinogens or teratogens should be well validated against known ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199000051-00006

    authors: Anderson D

    更新日期:1990-01-01 00:00:00

  • Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.

    abstract:INTRODUCTION:Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light of current debate about interchangeability, prescribers, some patient groups and decision makers are calling for additional post-marketing evidence...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00845-y

    authors: Belleudi V,Trotta F,Addis A,Ingrasciotta Y,Ientile V,Tari M,Gini R,Pastorello M,Scondotto S,Cananzi P,Traversa G,Davoli M,Trifirò G,Italian Biosimilar Network (ItaBioNet).

    更新日期:2019-12-01 00:00:00

  • Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands.

    abstract:BACKGROUND:In November 2009, a vaccination campaign against Influenza A (H1N1) was started in the Netherlands. The accelerated registration procedure of the vaccines used in this campaign and the use of these vaccines on a large scale indicated a need for real-time safety monitoring. OBJECTIVE:To describe the processi...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11539270-000000000-00000

    authors: van Puijenbroek EP,Broos N,van Grootheest K

    更新日期:2010-12-01 00:00:00

  • Vancomycin-Induced Thrombocytopenia: A Narrative Review.

    abstract::Thrombocytopenia has been reported as an adverse reaction of numerous drugs. Vancomycin is often overlooked as a culprit but has been associated with several cases of thrombocytopenia that were not well described in the literature. A literature search was conducted to find reports of thrombocytopenia induced by vancom...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0469-y

    authors: Mohammadi M,Jahangard-Rafsanjani Z,Sarayani A,Hadjibabaei M,Taghizadeh-Ghehi M

    更新日期:2017-01-01 00:00:00

  • Skin sensitivity and transdermal drug delivery. A review of the problem.

    abstract::Transdermal devices are now marketed for the delivery of systemic medication through the skin. Advantages associated with transdermal drug delivery include avoidance of first-pass metabolism and improved patient compliance. Drugs currently available by this route include scopolamine (hyoscine), nitroglycerin (glyceryl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199410020-00004

    authors: Carmichael AJ

    更新日期:1994-02-01 00:00:00

  • Improving safety reporting from randomised trials.

    abstract::Randomised clinical trials offer a unique opportunity for capturing safety information under a controlled setting that minimises biases in the comparison of different therapeutic options. Nevertheless, empirical evidence across diverse medical fields suggests that the reporting of safety information in clinical trials...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225020-00002

    authors: Ioannidis JP,Lau J

    更新日期:2002-01-01 00:00:00

  • Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

    abstract::Intranasal corticosteroids and intranasal antihistamines are efficacious topical therapies in the treatment of allergic rhinitis. This review addresses their relative roles in the management of this disease, focusing on their safety and tolerability profiles. The intranasal route of administration delivers drug direct...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326120-00003

    authors: Salib RJ,Howarth PH

    更新日期:2003-01-01 00:00:00

  • The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.

    abstract:BACKGROUND AND OBJECTIVE:Many drugs that are used to treat children are either not licensed for use in paediatric patients (unlicensed) or prescribed outside the terms of the product licence (off label). The incidence of adverse drug reactions (ADRs) associated with the use of such drugs is yet to be established. This ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427130-00006

    authors: Neubert A,Dormann H,Weiss J,Egger T,Criegee-Rieck M,Rascher W,Brune K,Hinz B

    更新日期:2004-01-01 00:00:00

  • Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

    abstract:OBJECTIVE:Minocycline is an antibacterial drug used in the treatment of acne. Concern has been expressed over the possibility of severe adverse reactions to minocycline, including hepatitis. This study set out to identify and characterise reported cases of hepatotoxicity associated with the use of minocycline. METHODS...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023040-00006

    authors: Lawrenson RA,Seaman HE,Sundström A,Williams TJ,Farmer RD

    更新日期:2000-10-01 00:00:00

  • Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.

    abstract::Drug-induced QT interval prolongation is now a major concern in safety pharmacology. Regulatory authorities such as the US FDA and the European Medicines Agency require in vitro testing of all drug candidates against the potential risk for QT interval prolongation prior to clinical trials. Common in vitro methods incl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427110-00002

    authors: Meyer T,Boven KH,Günther E,Fejtl M

    更新日期:2004-01-01 00:00:00

  • Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study.

    abstract:BACKGROUND:Pioglitazone is an antidiabetic drug that belongs to the thiazolidinedione (TZD) class of insulin-sensitizing agents. Adverse events to pioglitazone of potential severity are listed in the 'special warnings and special precautions for use' section of the pioglitazone summary of product characteristics (SPC),...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932030-00005

    authors: Fogg C,Kasliwal R,Shakir SA

    更新日期:2009-01-01 00:00:00

  • Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease.

    abstract::Benzodiazepine drugs have been shown to suppress respiratory function in patients with chronic obstructive pulmonary disease (COPD). We designed a placebo-controlled crossover study to compare the effects of a new benzodiazepine, estazolam ('ProSom'), with those of flurazepam ('Dalmane') on cardiopulmonary function in...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00002018-199207020-00006

    authors: Cohn MA,Morris DD,Juan D

    更新日期:1992-03-01 00:00:00

  • Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices.

    abstract::Pharmacovigilance is the science of monitoring the effects of medicinal products to identify and evaluate potential adverse reactions and provide necessary and timely risk mitigation measures. Intelligent automation technologies have a strong potential to automate routine work and to balance resource use across safety...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-01030-2

    authors: Huysentruyt K,Kjoersvik O,Dobracki P,Savage E,Mishalov E,Cherry M,Leonard E,Taylor R,Patel B,Abatemarco D

    更新日期:2021-02-01 00:00:00

  • Authors' Response to Braillon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring".

    abstract:: ...

    journal_title:Drug safety

    pub_type: 评论,信件

    doi:10.1007/s40264-018-0716-5

    authors: Simoons M,Seldenrijk A,Mulder H,van Roon E,Bakker R,Ruhé H

    更新日期:2018-12-01 00:00:00

  • Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

    abstract::Pharmacovigilance science has traditionally been a discipline focussed on the postmarketing or post-authorisation period, with due attention directed towards pre-clinical safety data, clinical trials and adverse events. As the biological sciences have evolved, pharmacovigilance has slowly shifted toward earlier, proac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629080-00003

    authors: Hartford CG,Petchel KS,Mickail H,Perez-Gutthann S,McHale M,Grana JM,Marquez P

    更新日期:2006-01-01 00:00:00

  • Drug-induced endocrine and metabolic disorders.

    abstract::Complex interactions exist amongst the various components of the neuroendocrine system in order to maintain homeostasis, energy balance and reproductive function. These components include the hypothalamus-pituitary- adrenal and -gonadal axes, the renin-angiotensin-aldosterone system, the sympathetic nervous system and...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200730030-00005

    authors: Ma RC,Kong AP,Chan N,Tong PC,Chan JC

    更新日期:2007-01-01 00:00:00

  • A risk-benefit assessment of HIV protease inhibitors.

    abstract::The use of triple regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the standard of care for persons with HIV initiating therapy by a number of sets of international guidelines. The widespread availabilit...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199920040-00002

    authors: Moyle GJ,Gazzard BG

    更新日期:1999-04-01 00:00:00

  • An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.

    abstract:BACKGROUND:Academic medical centres face the need to care for patients with complex medical conditions, educate physicians-in-training and conduct research, all with increasingly constrained budgets. The adoption of new therapeutic technology presents challenges and opportunities in each of these areas. Severe sepsis r...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427150-00008

    authors: Fischer MA,Lilly CM,Churchill WW,Baden LR,Avorn J

    更新日期:2004-01-01 00:00:00

  • The Effect of Positively Framing Side-Effect Risk in Two Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A Randomised Trial of 16- to 75-Year-Olds in England.

    abstract:INTRODUCTION:Reframing side-effect information in patient information leaflets (PILs) in terms of those who remain side-effect-free may reduce negative expectations and side-effects, although there are concerns this may impact informed consent. This study compared two versions of positively framed PILs with current pra...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00959-8

    authors: Webster RK,Rubin GJ

    更新日期:2020-10-01 00:00:00

  • Anticonvulsant-induced psychiatric disorders. The role of forced normalisation.

    abstract::With the introduction of several new anticonvulsant drugs into clinical practice in recent years, renewed attention has been paid to treatment-emergent effects, especially behavioural syndromes. In this review, the more severe psychiatric syndromes that may be associated with anticonvulsants are discussed, especially ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199615030-00001

    authors: Trimble MR

    更新日期:1996-09-01 00:00:00

  • The clinical implications of inhibition of the inducible form of cyclo-oxygenase.

    abstract::There are 2 isoenzymes of cyclo-oxygenase (COX). There is a constitutive enzyme COX-1 which has a wide tissue distribution. In addition there is an inducible enzyme COX-2 which has a restricted tissue distribution. The inducible enzyme COX-2 is responsible for the generation of prostaglandins at sites of tissue inflam...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199615040-00003

    authors: Richardson C,Emery P

    更新日期:1996-10-01 00:00:00

  • A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch.

    abstract::To estimate the frequency of adverse effects associated with the use of the transdermal nicotine patch, we abstracted and analysed data from 47 reports of 35 clinical trials. The meta-analysis presented here represents a synthesis of data from 41 groups of nicotine patch recipients totalling 5501 patients, and 33 grou...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析

    doi:10.2165/00002018-199818040-00005

    authors: Greenland S,Satterfield MH,Lanes SF

    更新日期:1998-04-01 00:00:00

  • Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance.

    abstract::In the original publication of the article, the trend line for non-EEA cases in figure 4 is incorrect. In this correction, the original Fig. 4 (Fig. 1) and the correct Fig. 4 (Fig. 2) are published. ...

    journal_title:Drug safety

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40264-018-0700-0

    authors: Newbould V,Le Meur S,Goedecke T,Kurz X

    更新日期:2018-12-01 00:00:00

  • Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.

    abstract:BACKGROUND:A number of published studies compare adverse event rates for drugs on the basis of reports in the US FDA Adverse Event Reporting System (AERS). While the AERS data have the advantage of timely availability and a large capture population, the database is subject to many significant biases, and lacks complete...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932020-00006

    authors: Hochberg AM,Pearson RK,O'Hara DJ,Reisinger SJ

    更新日期:2009-01-01 00:00:00

  • Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées region (PharmacoMIP) network 2-year pilot study.

    abstract:BACKGROUND:Spontaneous reporting of adverse drug reactions (ADRs) is fundamental to drug safety surveillance (pharmacovigilance); however, substantial under-reporting exists and is the main limitation of the system. Several factors could favour under-reporting. OBJECTIVE:The aim of this pilot study was to assess the e...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11319170-000000000-00000

    authors: Gony M,Badie K,Sommet A,Jacquot J,Baudrin D,Gauthier P,Montastruc JL,Bagheri H

    更新日期:2010-05-01 00:00:00